Georgia Medicaid Mental Health Drugs & Antipsychotics (2026)

Georgia Medicaid mental health drugs coverage is broad: Georgia Medicaid covers antidepressants, antipsychotics, mood stabilizers, and other psychiatric drugs. But a covered drug can still reject at the pharmacy counter. The drug has to clear the Georgia Preferred Drug List (PDL): a preferred drug fills with no extra step, while a non-preferred one needs prior authorization (PA) first. Federal law gives you two protections when that happens, a decision within 24 hours of a complete request and at least a 72-hour emergency supply, so your prescription is not supposed to stop while paperwork moves. This guide explains why a covered drug rejects, how the Georgia Department of Community Health (DCH) PDL and prior authorization work, the special rules for nursing-home antipsychotics, and which card pays when you have both Medicare and Medicaid.

In This Guide

• Key Operative Rules
• How Georgia Medicaid Mental Health Drugs Are Covered (and Why One Rejected)
• How Prior Authorization and Step Therapy Work
• The Mental Health Parity Backstop
• Nursing-Home Antipsychotics and Your Family's Rights
• Which Card Pays If You Have Medicare and Medicaid
• Who Administers Your Pharmacy Benefit in Georgia
• Medications for Substance Use Disorder
• How to Appeal a Denial
• Frequently Asked Questions
• Learn More

Key Operative Rules

The figures below are the rules a Georgia family most often needs at the counter or in a care conference. The drug-specific details follow in the sections beneath.

How Georgia Medicaid Mental Health Drugs Are Covered (and Why One Rejected)

Almost every FDA-approved drug is technically coverable by Georgia Medicaid, because of how federal drug-coverage law is built. Under the Medicaid Drug Rebate Program (Social Security Act Section 1927), a manufacturer must pay the state a rebate on covered outpatient drugs to have those drugs covered. For a brand drug the basic rebate is the greater of the difference between the average manufacturer price and the best price, or 23.1% of the average manufacturer price; for a generic it is 13% of that price.7 Those rebates plus federal matching give the state a financial reason to cover broadly, so a psychiatric drug is rarely excluded outright.

What changes whether the drug fills today is the Preferred Drug List. Federal law (Social Security Act Section 1927(d)) lets a state both subject a covered drug to prior authorization and maintain a formulary that steers prescribing, which is the legal basis for a PDL on which non-preferred drugs require PA.2 The PDL is not a closed list: a non-preferred drug is still covered, just with extra administrative steps. Georgia keeps a single statewide PDL and one set of PA criteria, maintained by DCH, that apply to fee-for-service members and to every managed-care plan alike.1 Drug-to-tier assignments shift over time, so pull the current DCH PDL for the operative classification of any specific drug.

In broad terms, generic SSRIs (such as sertraline, escitalopram, and fluoxetine), common generic atypical antipsychotics (such as risperidone, olanzapine, and quetiapine), generic mood stabilizers, and generic anxiolytics tend to sit at the preferred tier with no PA. Newer agents without a generic equivalent, and specialty drugs such as esketamine for treatment-resistant depression and brexanolone for postpartum depression, tend to require PA, step therapy, or specialty-pharmacy delivery. Confirm any individual drug against the current DCH list rather than relying on this general orientation.

How Prior Authorization and Step Therapy Work

Prior authorization is the approval a prescriber must obtain before a non-preferred drug is dispensed. The request carries the diagnosis, prior treatment history, and clinical justification, and the plan or its pharmacy benefits manager either approves it, denies it, or asks for more information.

Two federal protections bound that process, and they are the most actionable facts on this page. Under Social Security Act Section 1927(d)(5), the PA system must provide a response within 24 hours of a complete request, and it must allow the pharmacy to dispense at least a 72-hour emergency supply of a covered outpatient drug when a decision cannot be made in time.2 For psychiatric medication, where an abrupt interruption can be dangerous, that 72-hour supply is the protection to ask the pharmacist for by name if a claim rejects.

Step therapy is the related requirement to try a lower-tier drug before a higher-tier one is covered. For antidepressants, a typical pattern is to try a generic SSRI at a therapeutic dose for an adequate duration, then a second generic or an atypical antidepressant, before a branded SSRI, an SNRI, or a newer agent is approved. The same federal authority that allows a PDL also preserves a prescriber's right to override the list with documentation of medical necessity, such as a contraindication or a documented prior failure of the required step-therapy drug.2 The plan or pharmacy benefits manager must accept appropriate documentation rather than enforce the step mechanically.

The Mental Health Parity Backstop

Whatever utilization management a Medicaid plan applies to a psychiatric drug, it cannot be more restrictive than the management it applies to comparable medical and surgical drugs. The Mental Health Parity and Addiction Equity Act of 2008 (MHPAEA) requires that financial requirements and treatment limitations, including non-quantitative limitations such as prior authorization, step therapy, and formulary design, on mental-health and substance-use-disorder benefits be no more restrictive than those applied to medical and surgical benefits.8 That standard reaches Georgia's Medicaid managed care through the 2016 Medicaid and CHIP parity final rule (81 FR 18390), which applied MHPAEA to Medicaid managed care organizations, Alternative Benefit Plans, and the Children's Health Insurance Program.9

The practical lever for a family: if your psychiatric drug carries step therapy or a quantity limit that comparable medical drug classes do not, that difference is a parity question the plan must be able to justify. Georgia adds a state layer on top of the federal floor. Georgia's Mental Health Parity Act (House Bill 1013), signed April 4, 2022 and codified in part at O.C.G.A. Section 33-21A-13, requires state-regulated insurers to cover mental-health and substance-use-disorder benefits in parity with physical-health benefits, and DCH and the Office of the Insurance and Safety Fire Commissioner maintain parity complaint portals for Medicaid, PeachCare for Kids, and other affected plans.10 Parity does not ban utilization management; it requires that the management be applied evenhandedly across mental-health and medical benefits.

Nursing-Home Antipsychotics and Your Family's Rights

For a loved one in a nursing facility on an antipsychotic for dementia behaviors, the live question is usually not whether Medicaid pays. It is whether the drug is a clinically justified treatment or a chemical restraint, and federal nursing-facility rules answer that with specific guardrails.

Two clinical facts frame the decision. Antipsychotic drugs carry an FDA Boxed Warning that older adults with dementia-related psychosis treated with antipsychotics face about 1.6 to 1.7 times the risk of death of those given a placebo, and no antipsychotic is FDA-approved to treat dementia-related psychosis.4 That warning applies to both second-generation (atypical) and first-generation (conventional) antipsychotics.

Federal rule 42 CFR 483.45 then sets the operating rules inside a Medicaid- or Medicare-certified facility. Each resident's drug regimen must be free of unnecessary drugs, meaning no drug used in excessive dose, for excessive duration, without adequate monitoring, without adequate indication, or in the presence of adverse consequences. A resident on a psychotropic drug must receive gradual dose reductions and behavioral interventions, unless clinically contraindicated, in an effort to discontinue the drug; an as-needed (PRN) psychotropic order is limited to 14 days; and a licensed pharmacist must review each resident's drug regimen at least once a month.5

For a family, those rules translate into the questions worth asking in a care conference:

• What specific diagnosed condition and behavioral target is the drug treating, and is it documented?
• What non-pharmacologic interventions were tried first?
• Has gradual dose reduction been attempted, and if not, why is it clinically contraindicated?
• What monitoring is in place, and was the FDA Boxed Warning discussed before consent?

If those answers are missing, the Georgia Long-Term Care Ombudsman (1-866-552-4264) can review the documentation and advocate on the resident's behalf.

Which Card Pays If You Have Medicare and Medicaid

For a dual eligible (someone with both Medicare and full Georgia Medicaid), outpatient psychiatric drugs are covered through Medicare Part D, not Medicaid pharmacy. The card to hand the pharmacist for a psychiatric drug is the Part D card.

Part D gives psychiatric drugs unusually strong protection. Plans must cover "all or substantially all" drugs in six protected classes, codified at 42 CFR 423.120(b)(2)(v): antidepressants, antipsychotics, anticonvulsants, immunosuppressants for transplant rejection, antiretrovirals, and antineoplastics. For these classes a plan may apply prior authorization or step therapy only to new starts (people not already on the drug), and never to antiretrovirals.3 Benzodiazepines and barbiturates, once excluded from Part D, are now covered for prescriptions dispensed on or after January 1, 2013 under Section 175 of the Medicare Improvements for Patients and Providers Act of 2008 (barbiturates only when used for epilepsy, cancer, or a chronic mental-health disorder).11

Cost is rarely the barrier for a dual eligible, because full duals qualify for the Part D Low-Income Subsidy (Extra Help), available below 150% of the federal poverty level (about $1,995 a month for an individual in 2026). Full Extra Help recipients pay no more than $5.10 for a covered generic and $12.65 for a covered brand drug in 2026, and $0 once out-of-pocket drug costs reach the $2,100 annual catastrophic cap.6 In 2026 the standard Part D benefit also caps total out-of-pocket spending on covered drugs at $2,100, after a deductible of no more than $615, with the former coverage gap eliminated.12 Georgians with both coverages can also enroll in a Dual Eligible Special Needs Plan (D-SNP), a Medicare Advantage plan built for people with Medicare and Medicaid; DCH placed a moratorium on contracting with new D-SNPs effective August 1, 2025 while keeping existing D-SNP contracts in place.13

Who Administers Your Pharmacy Benefit in Georgia

Who actually adjudicates a member's psychiatric-drug claim depends on how that member is enrolled, but the rules they apply are the same statewide list. For the fee-for-service population, OptumRx is the pharmacy benefits manager for the Georgia Medicaid fee-for-service outpatient pharmacy program, processing claims at the point of sale. Members in a Georgia Families managed-care plan get their pharmacy benefit through their plan and its own pharmacy benefits manager instead.1

Georgia Families runs three current care management organizations (CMOs): Amerigroup Community Care of Georgia, CareSource Georgia, and Peach State Health Plan. All three are bound to the same statewide DCH Preferred Drug List and prior-authorization criteria, so a member cannot switch plans to get a more favorable psychiatric-drug formulary the way a Medicare Part D enrollee can.14 When a member changes plans or a plan changes pharmacy benefits managers, transition fills are meant to keep existing prescriptions filling for a defined window while updated PA documentation is submitted, though disruptions do happen in practice.

Medications for Substance Use Disorder

Substance use disorder medications run through the same PDL and pharmacy benefit, with a few specifics. Buprenorphine (sold as Suboxone, Subutex, and Sublocade) is covered for opioid use disorder; the Mainstreaming Addiction Treatment (MATE) Act, enacted as Section 1262 of the Consolidated Appropriations Act, 2023, eliminated the former DATA-2000 DEA X-waiver, so any practitioner whose DEA registration includes Schedule III authority may now prescribe buprenorphine for opioid use disorder, if state law permits.15 Naltrexone (oral and the monthly Vivitrol injection) is covered for both opioid and alcohol use disorder, with the injectable billed under the medical benefit. Acamprosate and disulfiram are covered for alcohol use disorder. Methadone for opioid use disorder may be dispensed only through a Substance Abuse and Mental Health Services Administration (SAMHSA)-certified, DEA-registered Opioid Treatment Program (OTP), not at a retail pharmacy or by an office-based prescriber.16 The parity rules above apply to these medications as fully as to any other drug class.

How to Appeal a Denial

When a prior authorization is denied, you have appeal rights, and the deadlines are stated in the denial notice itself, so read it as soon as it arrives.

Brevy's Georgia Medicaid appeals and fair hearings guide walks through the process in detail, and Disability Rights Georgia can assist with complex or dual-track appeals.

Key Contacts for Georgia Medicaid Mental Health Drug Coverage

Learn More

Find personalized help navigating Georgia Medicaid mental health drug coverage at brevy.com.

The information on Brevy.com is for educational purposes only and is not a substitute for professional legal, financial, or medical advice. Rules vary by state and program and change frequently. Always verify with the relevant agency or a qualified professional. Brevy is not a law firm, financial advisor, or healthcare provider.